CARB-X FUNDS MODULE INNOVATIONS TO DEVELOP A SIMPLE TEST TO DIAGNOSE URINARY TRACT INFECTIONS (UTI) AND IDENTIFY SUPERBUGS CAUSING THE INFECTION WITHIN 2 HOURS
CARB-X announced today it is awarding Module Innovations of Pune, India, up to US$702,000 plus up to $2.5 million more if certain project milestones are met, to develop a rapid diagnostic for drug-resistant urinary tract infections (UTI) infections. The diagnostic would also provide vital information on which antibiotics would be most effective against the superbug, including common uropathogens such as Escherichia coli, Klebsiella, Pseudomonas aeruginosa and Enterococci faecalis that often cause infection.
The phenotypic test, ASTSENSeTM for rapid antibiotic susceptibility testing (AST) of UTIs, would shave days off the time it takes to diagnose a UTI. A simple, non-invasive urine sample would be loaded into the ASTSENSe device, which would diagnose an infection and provide the antibiotic resistance profile of the pathogen(s) involved within two hours.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
